Employee Spotlight: Jérôme Maës, Director, Global Project Lead
In today’s blog, it is our pleasure to introduce you to Jérôme Maës, Director, Global…
Our Company
Developing a suite of photoreceptor-targeted gene-agnostic gene therapies for blinding retinal diseases.
SparingVision is a clinical-stage gene-agnostic gene therapy company focused on preserving and restoring vision. We take a gene-agnostic approach that leverages the natural function of light-sensing cone receptors, enabling patients to maintain the eye’s native visual pathways. This means patients can avoid the need for cell replacement, a last resort procedure, or technologies that bypass the eye’s natural signaling pathways, such as optogenetics.
Our Goal
To bring cutting-edge treatments that leverage the natural function of photoreceptors to preserve visual function, slow disease progression, and ultimately restore sight in patients with blinding retinal diseases.
Pipeline
At the heart of this, we are developing a suite of photoreceptor-targeted gene-agnostic gene therapies for inherited retinal diseases (IRD) such as retinitis pigmentosa (RP), as well as dry age-related macular degeneration (AMD) and geographic atrophy (GA).
Retinitis Pigmentosa
A group of IRDs which are a leading cause of blindness globally. Current treatment approaches are not applicable to all patients, regardless of genetic background or disease stage. With our comprehensive gene-agnostic, gene therapy approach for RP, we believe that we could preserve visual function at any stage in the evolution of the disease, from its diagnostic until its late stage evolution, and restore function whenever a loss of function has occurred.
SPVN06 Neuroprotection
SPVN06 is a breakthrough investigational gene-agnostic therapy designed to preserve sight and slow disease progression in patients with inherited retinal diseases (IRDs) and other blinding diseases such as age-related macular degeneration (AMD).
Learn More
SPVN20 Neuroenhancement
SPVN20 is a pioneering investigational gene-agnostic therapy that aims to restore vision through the retina’s native pathway in patients with inherited retinal diseases (IRDs)
Learn More
Combining 20+ years of world-leading ophthalmic research with a world class team of experts from across the international drug development spectrum. SparingVision has an unparalleled understanding of retinal disease and bringing novel treatments to patients.
Investors
Public Funding
